Collective years investing in healthcare
Working with MVM
MVM partners with best-in-class management teams to bring innovative products to market, drive growth, make strategic acquisitions, and establish new standards of care in medicine.
We seek out portfolio companies that address significant unmet needs in large addressable markets. These include medical conditions for which there is no adequate treatment, therapies for which existing technologies are too expensive, or diseases for which there is no accurate diagnostic capability, among other situations.
In all of these cases, we prioritize businesses that have a clearly differentiated technology with durable protection against competition, whether through intellectual property, barriers to market entry, statutory exclusivity, or unique branding. After investment, we work closely with management teams to help the business achieve both its near and long term goals.
While MVM does not use fixed investment criteria, we focus on companies that fit the following profile.
We provide growth equity to commercial-stage businesses. In other words, our investments are intended to accelerate the growth and scale of companies that have commercially available products.
We invest broadly across healthcare and life sciences. We have made investments in medical devices, pharmaceuticals, diagnostics, digital health, health IT, life science tools, contract research, and contract manufacturing, among other areas. We focus on identifying differentiated products or technologies in each of these categories.
We expect to make aggregate investments of $10 to 50 million in each of our portfolio companies over the life of our holding. In select circumstances, we have the capacity to make larger investments to support unique or creative financing opportunities.
MVM invests in innovative healthcare companies. Our active portfolio companies are transforming the delivery of healthcare by enabling higher quality, cost-effective care in large, global markets. We maintain a concentrated portfolio, focused on building world-class companies.
MVM has extensive experience guiding our portfolio companies to successful exits, including both acquisitions and initial public offerings. Selected former portfolio companies include:
MVM invests in Nalu Medical
February 17, 2022
CARLSBAD, Calif. (PRWEB) February 17, 2022 Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]
Clarivate acquires Patient Connect
December 22, 2021
Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]
MVM invests in Vero Biotech
December 15, 2021
VERO Biotech Inc., a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the […]
MVM Invests In Optinose
November 18, 2021
MVM invested $20 million in Optinose. Optinose markets XHANCE, an innovative drug delivery system that delivers steroids high and deep […]
Paragon 28, Inc. Announces Pricing of Initial Public Offering
October 15, 2021
ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ — Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and […]
MVM invests in InBrace
September 8, 2021
MVM invested $15 million in InBrace. InBrace is an orthodontic company that created the novel SmartwireTM, a new category in […]
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
August 6, 2021
Saint Herblain (France), August 5, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the […]
Vertos mild® Patients Demonstrate Durable 5 Year Outcomes
May 18, 2021
Most Minimally Invasive Lumbar Decompression (mild®) providers are very familiar with the 1-year study conducted by Nagy Mekhail, MD, PhD […]
Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
May 11, 2021
Saint-Herblain (France), May 6, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for […]
Old City Hall, 45 School Street
Boston MA 02108
30 St George Street
London W1S 2FH